ABL Diagnostics (XPAR:ABLD) FCF Margin % : -6.47% (As of Jun. 2023)

View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ABL Diagnostics's Free Cash Flow for the six months ended in Jun. 2023 was €-0.19 Mil. ABL Diagnostics's Revenue for the six months ended in Jun. 2023 was €2.88 Mil. Therefore, ABL Diagnostics's FCF Margin % for the quarter that ended in Jun. 2023 was -6.47%.

As of today, ABL Diagnostics's current FCF Yield % is -0.38%.

The historical rank and industry rank for ABL Diagnostics's FCF Margin % or its related term are showing as below:

XPAR:ABLD' s FCF Margin % Range Over the Past 10 Years
Min: -164.14 Med: -53.87 Max: 56.4
Current: -1.6

During the past 13 years, the highest FCF Margin % of ABL Diagnostics was 56.40%. The lowest was -164.14%. And the median was -53.87%.

XPAR:ABLD's FCF Margin % is ranked worse than
57.49% of 668 companies
in the Healthcare Providers & Services industry
Industry Median: 1.26 vs XPAR:ABLD: -1.60

ABL Diagnostics FCF Margin % Historical Data

The historical data trend for ABL Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics FCF Margin % Chart

ABL Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-164.14

ABL Diagnostics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-6.47

Competitive Comparison of ABL Diagnostics's FCF Margin %

For the Health Information Services subindustry, ABL Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Diagnostics's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's FCF Margin % falls into.

ABL Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ABL Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	0	/	8.749
	=	0.00 %

ABL Diagnostics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-0.186	/	2.876
	=	-6.47 %

ABL Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Diagnostics (XPAR:ABLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

72c, rue de, WOIPPY, Thionville, FRA, 57140

Website

https://www.abldiagnostics.com

ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines